Theravance Biopharma details January 2026 presentation

Theravance Biopharma, Inc. filed a Form 8-K to furnish an investor presentation under Regulation FD.

Accepted by SEC EDGAR 01/12/2026 - 08:01 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Theravance Biopharma, Inc. filed a Form 8-K to furnish an investor presentation under Regulation FD. Members of the management team are holding one-on-one meetings with analysts and investors in San Francisco, California from January 12–15, 2026, using a corporate slide presentation. That slide deck, entitled “Corporate Presentation – January 2026”, is provided as Exhibit 99.1 and incorporated by reference into the report.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Theravance Biopharma (TBPH) report in this Form 8-K?

Theravance Biopharma, Inc. furnished an investor slide presentation under Regulation FD, filed as a Form 8-K with the SEC.

What is included in Exhibit 99.1 for Theravance Biopharma (TBPH)?

Exhibit 99.1 is a slide deck entitled “Corporate Presentation – January 2026”, which management is using in meetings with analysts and investors.

When and where is Theravance Biopharma (TBPH) meeting with investors?

Theravance Biopharma management is conducting one-on-one meetings with analysts and investors in San Francisco, California from January 12–15, 2026.

Is the Theravance Biopharma (TBPH) presentation deemed filed with the SEC?

No. The information in this report, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act.

Does this Theravance Biopharma (TBPH) Form 8-K add to any registration statements?

The report states that the furnished information, including Exhibit 99.1, will only be incorporated by reference into a registration statement if specifically referenced in such filing.

Are there financial statements included in this Theravance Biopharma (TBPH) 8-K?

Under Item 9.01, the company lists only exhibits, including the January 2026 corporate presentation and the cover page interactive data file.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001583107 0001583107 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

FORM 8-K

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): January 12, 2026

THERAVANCE BIOPHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

Cayman Islands		001-36033		98-1226628
(State or Other Jurisdiction of		(Commission File Number)		(I.R.S. Employer Identification
Incorporation)				Number)

c/o Theravance Biopharma US, LLC

901 Gateway Boulevard

South San Francisco, CA 94080

(650) 808-6000

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Share $0.00001 Par Value		TBPH		NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company    ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation FD Disclosure.

The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 

Members of the Theravance Biopharma management team will be conducting one-on-one meetings with analysts and investors in San Francisco, CA from January 12-15, 2026, using a slide presentation which is being furnished pursuant to Regulation FD as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

	99.1	Slide deck entitled Corporate Presentation – January 2026
	104	Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	THERAVANCE BIOPHARMA, INC.
Date: January 12, 2026	By:	/s/ Brett Grimaud
		Brett Grimaud
		General Counsel